Kornimate/medical-research-clean huggingface dataset:
effect of senobi versus buteyko technique on functional performance of chronic obstructive pulmonary disease patient.

Conditions: Shortness of Breath

Summary: effect of senobi breathing exercise versus buteyko breathing technique on functional performance among chronic obstructive pulmonary patient.

chronic obstructive pulmonary disease is a chronic inflammatory lung disease that cause obstructed airflow from the lungs. symptoms include breathing difficulty. cough, mucus production and wheezing. its typically caused by long term exposure to irritating gasses or particulate matter, most often from cigarette smoker. emphysema and chronic bronchitis are two most common condition that contribute to chronic obstructive pulmonary disease. chronic obstructive pulmonary disease is progressive disease that gets over a time. clinical trials will be conducted in gulab devi chest hospital in lahore. through the convenient sampling technique. which will be allocated through the random sampling two groups are involved group a and group b. in group a check the effect of senobi techniques (stretch the body) and in group b check the effect of buteyko technique. (inhale the through the nose while mouth is closed) by using 6 mint walk test, borg scale and quality of life questionnaire. apply the technique to check the effectiveness of dyspnea and quality of life of patient the buteyko technique offers a complementary method of reliving respiratory symptoms based on the voluntary control of breathing as well as considering the effect of environmental and dietary trigger. data will be collected by the questionnaire and analyzed by using statistical package for the social science spss software version 21. the buteyko method made its way to australia to europe and the unite states in 1990, it become best for the asthma and chronic obstructive pulmonary disease patient. the senobi stretch exercise of the respiratory muscle improve the chest expansion and also improve the chest wall mobility in chronic obstructive pulmonary disease patient. senobi breathing exercise was found to be effective for depression and it regulate the sympathetic nerve activity.

Eligibility criteria:
inclusion criteria: * age 40 -80 * copd patient in stage 2 (gold criteria) * dyspnea (fev1\< 70 %)(26) * maximum expiratory pressure: 50% * smoker exclusion criteria: * patient with tumor * patient with cardiac arrhythmias patient * patient with cancer * insulin dependent diabetes * patient with thyroid disease

Keywords: dyspnea, quality of life, senobi,and buteyko
study of shr-1701 plus bp102 in subjects with selected solid tumors

Conditions: Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer

Summary: the main purpose of this study was to assess the safety,efficacy and pharmacokinetic when combining shr-1701 and bp102 in participants with advanced or metastatic non-squamous non-small cell lung cancer. to explore the immunogenicity of shr-1701 and the relationship between corresponding biomarkers and therapeutic effect.


Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed advanced or metastatic non-squamous non-small cell lung cancer. 2. failed with prior systemic treatments. 3. measurable disease, as defined by recist v1.1 4. the eastern cancer cooperative group (ecog) performance status of 0 or 1 5. life expectancy ≥ 3 months 6. adequate hematologic and end-organ function as defined in the protocol exclusion criteria: 1. histologically or cytologically confirmed mixed sclc and nsclc. 2. symptomatic, untreated or active central nervous system metastases. 3. systemic therapy with immunosuppressive agents within 2 weeks prior to initiation of study treatment 4. with any active autoimmune disease or history of autoimmune disease. 5. inadequately controlled hypertension. 6. tumor infiltration into the great vessels on imaging. 7. history of hemoptysis ≥2.5ml per episode within 1 month prior to initiation of study treatment. 8. uncontrolled tumor-related pain. 9. patients with active hepatitis b or hepatitis c 10. severe infections within 4 weeks prior to initiation of study treatment. 11. active tuberculosis within one year prior to initiation of study treatment.
docusate/senna for the treatment of diabetic gastroparesis

Conditions: Diabetic Gastroparesis

Summary: the aim of the study is to evaluate the efficacy of the stimulant laxative senokot-s® for the treatment of diabetic gastroparesis. senokot-s, and its metabolites, are thought to produce peristalsis, drive intraluminal fluid and electrolyte shifts, and have an irritant effect on the gut mucosa. these complex physiologic mechanisms appear may sufficiently promote stomach emp-tying, and thereby reduce or eliminate the severity of gastroparesis symptoms. in this open label study, participants will be randomized into high and low dose groups to assess for ideal dosing and tolerability. it is the overall goal of this study to select the most promising dose-strength for the treatment of mild through severe gastroparesis.


Eligibility criteria:
inclusion criteria: * age 18-75 years, male and non-pregnant, non-lactating females * diagnosis of type 1 or type 2 diabetes mellitus * clinical diagnosis of diabetic gastroparesis exclusion criteria: * diagnosed idiopathic gastroparesis * a history or inflammatory bowel disease, such as crohn's disease or ulcerative colitis * a history of bowel obstruction, current unexplained abdominal pain, or undiagnosed rectal bleeding * gastrointestinal cancer * any active cancer * prior gastric surgery * end-stage heart disease, liver disease, lung disease * known or suspected drug abuse * any condition requiring use of daily narcotics * concurrent usage of mineral oil or products containing mineral oil * current or recent (within the last 3 months) usage of senokot-s, docusate or senna
low level laser therapy to reduce comorbidity in spinal surgery

Conditions: Failed Back Surgery Syndrome

Summary: each year, more than one million individuals worldwide are submitted to laminectomies, with a failure rate higher than 40%. postlaminectomy epidural adhesion is implicated as a main cause of ''failed back surgery syndrome'' and associated with increased risk of complications during revision surgery. the postoperative epidural scar can cause extradural compression or dural tethering, which results in recurrent radicular pain and physical impairment. several studies in the literature are signalizing that low-level-laser-therapy (lllt) is proven to be an effective tool to assist the inflammatory process and wound healing, as well to prevent infection. thus, the objectives of this project are to delineate and evaluate the lllt effects in spinal surgery. a prospective randomized, controlled trial with a total of 48 patients who underwent laminectomy, were divided into 2 groups. in the first group, 25 patients received lllt during the surgical procedure over dura mater, over subcutaneous and on the skin, as well as 24h and 72h post surgery. in the second group, 23 patients were induced to think they will be getting the same treatment, although the laser is not operating. in those groups, c reactive protein, lactate dehydrogenase and creatine kinase were evaluated in the second and fifth days after surgery, digital temperature will be measured and scores in visual analogue scale will be used, 5 minutes pre and 5 minutes post laser application. the drainage output was collected in the first three days following surgery in both groups. interleukins were evaluated in interstitial infiltrate drained in 24h and 48h. the data was evaluated for normality and subjected to appropriate statistical analysis, in order to seek representation, as same as the level of significance of the studied samples.


Eligibility criteria:
inclusion criteria: * patients undergoing to lumbar laminectomy exclusion criteria: * active lumbar cancer * infectious disease * coagulation disorders * dural injury during the surgery

Keywords: lower level laser therapy (lllt) inflammation cytokines wound healing laminectomy clinical study
physical condition and bariatric surgery

Conditions: Obese Patients With Bariatric Surgery

Summary: the aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.

physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery. between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups: * control * control + protein supplementation * training in aquabike * training in aquabike + protein supplementation * bicycle training * bicycle training + protein supplementation

Eligibility criteria:
inclusion criteria: * male or female * age between 18 and 60 years * body mass index: bmi\> 40 kg / m2 * candidates for bariatric surgery exclusion criteria: * subject under 18 or over 60 years of age * biological assessment considered abnormal by the investigator * hiv serology or known positive hcv * pregnant or nursing women * for women of childbearing age: beta-hcg positive dosage or absence of contraception deemed reliable (oral contraceptive, iud, implant or hormonal patch) * medical or surgical history (judged by the investigator to be inconsistent with the study) * subject with cardiorespiratory and / or osteo-articular disorders limiting their ability to perform physical tests or training * subject with cardiovascular or neoplastic disease * subjects with an infection in the 3 months prior to inclusion * hypercorticism and uncontrolled dysthyroidism * patient with known neuro-muscular pathology: myopathy, myasthenia gravis, rhabdomyolysis, paraplegia, hemiplegia * patient with chronic or acute inflammatory disease the 3 months before inclusion * crp\> 20 mg / l * person treated with or having stopped treatment for less than 3 months prior to inclusion by corticosteroids, immunosuppressant, anabolic agent, growth hormone * person with an unstable psychiatric condition * blood donation in the two months preceding the study * high alcohol consumption (\> 2 to 3 drinks per day depending on sex) or presence of drug addiction * significant smoking (\> 5 cigarettes / day or equivalent in cigars or pipe tobacco) * intense sports activity (\> 5 hours / week) * subjects excluded from another study or having received more than 4500 € in the year following their participation in clinical studies

Keywords: bariatric surgery morbid obesity physical condition muscle 6-minute walking test protein supplementation physical activity program
a clinical study in three-arm of lurbinectedin (pm01183) alone or in combination with gemcitabine and a control arm with docetaxel as second line treatment in non-small cell lung cancer (nsclc) patients

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Summary: a clinical study of lurbinectedin(pm01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (nsclc)patients

a randomized-controlled, three-arm, phase ii study of lurbinectedin (pm01183) alone or in combination with gemcitabine and a control arm with docetaxel as second-line treatment in unresectable non-small cell lung cancer (nsclc)patients to evaluate the antitumor activity as progression-free survival at four months (pfs4) of pm01183 alone or in combination with gemcitabine as using single agent docetaxel as a reference in the control arm as current standard of care and to analyze overall survival (os), overall survival rate at 1-year (os12), duration of response (dr), antitumor activity, as response rate (rr), safety and efficacy profiles of pm01183 alone and in combination with gemcitabine, to be preliminary compared with docetaxel, patients' quality of life (qol), pharmacokinetics (pk) of pm01183, pharmacokinetic/pharmacodynamic (pk/pd)correlation and pharmacogenomics (pgx)to explore potential correlations between clinical outcomes and molecular parameters found in tumor and blood samples

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed unresectable nsclc * patients must have failed one prior line of ct-based therapy for unresectable disease * age between 18 and 75 years * eastern cooperative oncology group (ecog)performance status (ps) ≤ 1 * adequate hematological, renal, metabolic and hepatic function * at least three weeks since the last prior therapy, at least four weeks since completion of any prior radiotherapy * negative pregnancy test for pre-menopausal women exclusion criteria: * concomitant diseases/conditions as unstable angina, myocardial infarction, symptomatic congestive heart failure or asymptomatic with left ventricular ejection fraction (lvef) ≤ 50%, dyspnea, infection by human immunodeficiency virus (hiv), active hepatitis b virus (hbv) or hepatitis c virus (hcv) infection, active uncontrolled infection, pleural or pericardial effusions, myopathy, limitation of the patient's ability to comply with the treatment or to follow-up the protocol, any other major illness * histological features of neuroendocrine or bronchioalveolar differentiation. * unknown epidermal growth factor receptor (egfr)mutation status or previously known egfr mutated status in patients with adenocarcinoma. * prior or concurrent invasive malignant disease, unless in complete remission for more than three years. * significant cancer-related weight loss (≥10%)within four weeks prior to treatment start * prior treatment with docetaxel-containing therapy * symptomatic, steroid-requiring or progressive central nervous system (cns) involvement * paraneoplastic syndromes
study of ranolazine in myotonia congenita, paramyotonia congenita and myotonic dystrophy type 1

Conditions: Myotonia Congenita; Paramyotonia Congenita; Myotonic Dystrophy 1

Summary: the purpose of this study is to gather preliminary data to determine if ranolazine is a safe and effective treatment for the symptoms of myotonia congenital, paramyotonia congenita, and myotonic dystrophy type 1. the duration of the study is 5 weeks.

recent advances in the understanding of myotonia congenita have identified potential areas that could possibly respond to treatment in a drug study. the drug ranolazine (trade name ranexa) is a fda-approved medication to treat chest pain in patients with heart disease. ranolazine has been studied in mice with myotonia congenita. the data from this animal model suggest that ranolazine may improve the symptoms and signs of myotonia. all individuals that participate will be placed on active drug. the investigators want to see if this drug is safe to take without causing too many side effects for people with myotonia congenita, paramyotonia congenital and myotonic dystrophy type 1. participants will go to the ohio state university for study visits. participants will take ranolazine for four weeks. participants can expect a total of 4 study visits and 2 phone calls over the 5 week period.

Eligibility criteria:
inclusion criteria: * diagnosis of myotonia congenital, paramyotonia congenital or myotonic dystrophy type 1 established by genetic testing in the subject or in a first-degree relative. * clinically evident myotonia exclusion criteria: * contraindications to ranolazine use: * for fungus infection: ketoconazole (nizoral), itraconazole (sporanox, onmel) * for infection: clarithromycin (biaxin) * for depression: nefazodone * for hiv: nelfinavir (viracept), ritonavir (norvir), lopinavir and ritonavir (kaletra), indinavir (crixivan), saquinavir (invirase). * for tuberculosis (tb): rifampin (rifadin), rifabutin (mycobutin), rifapentine (priftin) * for seizures: phenobarbital, phenytoin (phenytek, dilantin, dilantin-125), carbamazepine (tegretol) * the herbal supplement st. john's wort * you have scarring (cirrhosis) of your liver * concurrent use of mexiletine, lacosamide, acetazolamide, phenytoin, quinine, procainamide, saint john wort or tocainide. patients who were previously treated with these medications may participate. they need to be off of the medication for at least a week prior to enrollment. * qtc \>470 ms for men and \>480 ms for women. * women who are pregnant or breastfeeding * direct family history of sudden cardiac death

Keywords: myotonia congenita ranolazine ohio state open label paramyotonia congenita myotonic dystrophy 1
comparison of the effects of external focus and internal focus instructions applied chronic low back pain: rct

Conditions: Physical Therapy Techniques

Summary: postural control methods are impaired in people with chronic low back pain. while the person maintains balance with pain relief, fear of movement and pain increase with loss of balance. it was found that externally focused exercises are more effective than internal focus exercises in terms of motor control and motor learning. to investigate the place of externally focused balance exercises in conservative treatment of target low back pain. for this purpose, approval was obtained from the clinical research ethics committee of kırşehir ahi evran university, faculty of medicine, with the decision numbered 2022-18/163.

focusing on the inside of the body while performing a movement is called "internal (internal focus)", focusing on the outside of the body is called "external (external focus)". many previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement.in our randomized controlled study, there were two groups and 22 people were treated in each group. volunteers between the ages of 18-65 who had low back pain for the last 3 months and had no musculoskeletal problems were included. balances were evaluated with biodex balance device, pain with visual analog scale, performance with physical performance test battery, functional level with osvewstry disability index, posture, spinal mobility,postural endurance with spinal mouse device. 8 weeks of treatment were applied to both groups as external focus and control groups. basically similar exercises were applied to both groups, and there were tasks in the exercises in the external focus group, and the focus were on the task other than the exercise. the results of the study show that externally focused balance exercises are effective on dynamic balance, fall risk, stability limits, physical performance, posture, spinal mobility, and postural endurance in individuals with clbp.

Eligibility criteria:
inclusion criteria: * those with ongoing low back pain symptoms in the last three months (diagnosed with chronic low back pain), * individuals between the ages of 18-65 * pain level 3 or more according to vas * individuals who volunteer to participate in the study will be included. exclusion criteria: * individuals with lower extremity and spine orthopedic and neurological disorders, * having a musculoskeletal injury in the last 9 months, * surgery, injection, etc. for low back pain in the last 3 months. with a history of treatment * those who are doing any sports activity, * subjects who do not cooperate well will not be included in the study. inclusion and exclusion criteria will be the same for control group participants.

Keywords: physical therapy low back pain, external focus
lidocaine irrigation in shoulder arthroscopy

Conditions: Postoperative Pain; Analgesia

Summary: arthroscopic shoulder surgery is often associated with severe postoperative pain that is often significant enough to interfere with initial recovery and rehabilitation. the pain that can be difficult to manage without large dose of opioid. the study aim to explore the effect of continuous irrigation of fluids mixed with lidocaine and epinephrine for analgesic consumption and postoperative pain after shoulder arthroscopy.


Eligibility criteria:
inclusion criteria: * age 20-60 * both genders * shoulder arthroscopy * asa i-iii exclusion criteria: * drug allergy * psychiatric disorder * opioid dependence * liver disease * patient refuse

Keywords: postoperative pain lidocaine shoulder arthroscopy
proof-of-concept study to evaluate the safety and immunomodulatory effects of scv 07 as monotherapy or in combination with ribavirin in noncirrhotic subjects with chronic hepatitis c who have relapsed

Conditions: Chronic Hepatitis C

Summary: scv-07 (γ-d-glutamyl-l-tryptophan) is a new immunomodulatory compound that has been developed and patented both for composition and immunomodulatory use and is a synthetic dipeptide. the efficacy of scv 07 in treating chronic hepatitis c virus (hcv) infection is expected to arise from the drug's ability to stimulate the t-helper 1 (th1) type immune response and to block signal transducers and activator of transcription 3 (stat3) mediated signaling. the purpose of this study is to determine if scv-07 alone and/or scv-07 in combination with ribavirin is safe and potentially effective for the treatment of genotype 1 compensated chronic hepatitis c in subjects who have relapsed after a response to a previous treatment course of at least 44 weeks with pegylated interferon and ribavirin. all subjects will receive 4 weeks of scv-07 (lead-in phase), followed by 4 weeks of treatment with scv-07 in combination with ribavirin (combination treatment).


Eligibility criteria:
inclusion criteria: * adult subjects must have compensated liver disease * subjects must have a history of chronic hepatitis c (genotype 1), and must be relapsers * subject's hcv rna viral load must be \> or = 300,000 iu/ml * subjects must have documentation of a liver biopsy within the last 2 years exclusion criteria: * human immunodeficiency virus (hiv) infection or hepatitis b surface antigen (hbsag)-positive * clinical evidence of cirrhosis * autoimmune hepatitis or other autoimmune/immune-active diseases * insulin-dependent diabetes

Keywords: scv-07 relapsers hepatitis c
the use of cannabis (marijuana) and cannabidiol (cbd) among cancer patients: a pilot study

Conditions: Cancer

Summary: to collect information about how patients in the pain management clinic use cannabis/cbd, including how often it is used, why it is used (for example, to manage pain or other symptoms), and where patients get their information on cannabis/cbd for pain management

objectives primary objective: the primary objective of this study is to investigate the prevalence of current and prior cannabis and/or cbd use in cancer patients who present to the pain management clinic at mdacc. secondary objectives: the secondary objective is to investigate the reason for cannabis/cbd use (e.g. pain, neuropsychiatric symptoms, recreational or other use), degree of symptom improvement with use, frequency of use, methods of use (e.g. inhaled vs. ingested), sources of information on cannabis/cbd, and patient interest in learning more from their physicians about cannabis/cbd for cancer pain.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. cancer patients who present to the md anderson pain medicine clinic as a new patient or consult 3. willing to give informed consent 4. willing to complete the survey exclusion criteria: 1. refusal of informed consent 2. refusal to complete the survey 3. patients who previously completed the survey 4. patients who opt-out or change their mind after agreeing to participate 5. already an established patient at mdacc pain medicine clinic 6. patients scheduled to see dr abdi (pi).
hemostatic measures during laparoscopic cystectomy for endometrioma

Conditions: Endometrioma

Summary: laparoscopic excision of ovarian endometriotic cysts is generally recommended because it has been associated with a higher spontaneous conception rate, residual ovarian function after the procedure may be affected


Eligibility criteria:
inclusion criteria: * 18 to 35 years * unilateral endometriotic cyst exclusion criteria: anovulatory women women with decreased ovarian reserve women receiving hormonal treatment three months prior to surgery women with any contraindication to laparoscopy women with previous ovarian surgery possible ovarian malignancy.